Slides
Page 1
2023年8月期 第2四半期決算説明資料 業績予想 トピックス 補足資料業績概要 1 THE BEST QUALITY IN THE WORLD, TO THE WORLD FY2026 1Q Financial Results January 14, 2026 President and Representative Executive Officer Masaya Watanabe
Page 2
2023年8月期 第2四半期決算説明資料 業績予想 トピックス 補足資料業績概要 2 FY2026 1Q Financial Results FY26 1Q: Highlights 1. Recovery in China Business due to Resumption of “MANI DIA-BURS” Sales Regulatory approval received from Chinese authorities on October 29, 2025; sales resumed Four months after resumption (Nov–Feb): projected cumulative sales of ¥1,050 million, replenishing distribution inventory Sales are projected to reach over 80% of pre-recall levels in the latter half of FY26 (Mar–Aug) 2. Share Acquisition in German Distributor iRIS EYE GmbH (Equity-Method Affiliate) iRIS EYE Gmbh became an equity-method affiliate to expand the European surgical business through collaboration 3. Establishment of New Factory in China Local production in China to respond to domestic preferential policy, while thoroughly managing investment risks Establishment of a new global three-site production system: Vietnam, Smart Factory (Hanaoka), China
Page 3
2023年8月期 第2四半期決算説明資料 業績予想 トピックス 補足資料業績概要 3 FY2026 1Q Financial Results China Business: Resumption of “MANI DIA-BURS” Sales Background In March 2025, a voluntary recall of certain MANI DIA-BURS began due to incomplete product registration information with Chinese authorities. The recall was mostly completed by August. Regulatory approval for the recalled products was obtained in October 2025, and sales resumed. Sales progress after resumption The initial plan; to recover sales to 90% of pre-recall levels within two years The progress is ahead of schedule. Four months after resumption (Nov–Feb), cumulative sales are expected to reach 1,050 million yen, replenishing distribution inventory. ‒ About 70% of major public hospitals have repurchased ‒ About 50% of clinics have repurchased, continue to be active ‒ About 90% of distributors have repurchased Sales will reach over 80% of pre-recall levels in the latter half of FY26 (Mar–Aug) MANI Local Subsidiary in China (Sales Base) Distributor End Users Hospitals Clinics LD* *LD：Logistic Dealer Distribution Inventory
Page 4
2023年8月期 第2四半期決算説明資料 業績予想 トピックス 補足資料業績概要 4 FY2026 1Q Financial Results 2022 2023 2024 2025 2026 2027 2028 2029 2030 Share Acquisiton in German Distributor iRIS EYE GmbH Positioning of Europe in the Surgical Business: Europe accounts for about 30% of segment sales One of the key investment areas in the mid-term plan Strengths of iRIS EYE: Over 20 years of collaborative relationship with MANI Unique sales network and marketing capabilities within Germany Investment Overview: Acquired 36.67% of issued shares from major shareholder iRIS EYE became an equity-method affiliate Growth Initiatives Centered on iRIS EYE: Support for European ophthalmology hospital chains Expand sales into Eastern Europe Supply chain restructuring Expansion of customer contact points, including European KOL doctors For reference, please refer to the disclosure released on December 22, 2025 “Notice Regarding Share Acquisition of German Distributor iRIS EYE GmbH (Conversion to Equity-Method Affiliate) “ Standalone growth CAGR6% CAGR12% Standalone growth Sales increase through collaboration with MANI Sales Plan
Page 5
2023年8月期 第2四半期決算説明資料 業績予想 トピックス 補足資料業績概要 5 FY2026 1Q Financial Results Vietnam Factory (Global Mass Production) China Factory (Local Production for China) Japan Hanaoka Factory (Mother factory) Aims and Basic Policy Respond to China’s domestic preferential policy and strengthen competitiveness Introduce automated production technology from the Smart Factory for rapid startup Rent factory building → control investment and thoroughly manage risk Name MANI China (Foshan) Co., Ltd. Establishment April 2024 Location Foshan, Guangdong Province Investment ¥1.2 billion Products Start with ophthalmic knives, expand product lineup Mass production 2028 Establishment of New Factory in China (1): Response to Domestic Preferential Policy and Strengthening Competitiveness For reference, please refer to the disclosure released on January 14, 2026 “Notice Regarding Establishment of Chinese Manufacturing Subsidiary“
Page 6
2023年8月期 第2四半期決算説明資料 業績予想 トピックス 補足資料業績概要 6 FY2026 1Q Financial Results FY25 FY35 Vietnam Factory Hanaoka Factory (SF) China Factory From 2026: Sequential production of ophthalmic knives → JIZAI → vitreous forceps From 2028: Start of ophthalmic knife production→ Gradual expansion of product lineup Current products: eyeless needles, dia-burs, files, ophthalmic knives, etc. Ongoing production reforms Rollout SF production technology Local Production for China Mother Factory Global Mass Production The Smart Factory will serve as the mother factory, establishing a global automated production system Continuous production reforms at the Vietnam factory Establishment of New Factory in China (2): Global Production Roadmap
Page 7
2023年8月期 第2四半期決算説明資料 業績予想 トピックス 補足資料業績概要 7 FY2026 1Q Financial Results
Page 8
2023年8月期 第2四半期決算説明資料 業績予想 トピックス 補足資料業績概要 8 FY2026 1Q Financial Results 1Q sales reached the highest for a quarter, and operating income was the highest ever for 1Q Dental (resumption of sales of dia-burs in China) and Eyeless Needle (Asia) drove sales growth SG&A expenses were as planned. The recovery in dental profitability contributed to an overall operating income margin of 28.8% Ordinary income and net income increased due to higher operating income and forex gains Consolidated Financial Results Summary (¥ million) FY25 1Q Results （A） FY26 1Q Results （B） Changes in Amount (C=B-A) Changes in % (C/A) FY26 Forecasts （D) Forecast Progress Rate (B/D) Net sales 7,655 7,828 +173 +2.3% 32,800 23.9% Cost of sales [%] 2,653 [34.7%] 2,669 [34.1%] +15 +0.6% [(0.6%)] 11,400 [34.8%] 23.4% SG&A expenses [%] 2,893 [37.8%] 2,904 [37.1%] +10 +0.3% [(0.7%)] 12,200 [37.2%] 23.8% Operating income [%] 2,107 [27.5%] 2,255 [28.8%] +148 +7.0% [+1.3%] 9,200 [28.0%] 24.5% Ordinary income 2,298 2,686 +388 +16.9% 8,950 30.0% Net income 1,598 1,896 +297 +18.6% 6,450 29.4%
Page 9
2023年8月期 第2四半期決算説明資料 業績予想 トピックス 補足資料業績概要 9 FY2026 1Q Financial Results Operating Income to Profit Before Income Taxes (Details) FY25 1Q Results FY26 1Q Results YoY Notes Operating income 2,107 2,255 +148 Non-operating income 209 566 +357 Foreign exchange gains 144 492 +348 Increase due to yen depreciation Interest income 33 31 (2) Non-operating expenses 18 136 +118 Unoperated land-related costs 14 120 ＋106 Increase in depreciation related to Hanaoka Factory before operation Ordinary income 2,298 2,686 +388 Extraordinary income 12 17 +5 Extraordinary losses 4 0 (4) Profit before income taxes 2,306 2,703 +397 (¥ million)
Page 10
2023年8月期 第2四半期決算説明資料 業績予想 トピックス 補足資料業績概要 10 FY2026 1Q Financial Results Net Sales Status by Segment Increase in sales YoY +173 million [+2.3%] Increase in the Dental and Eyeless Needle segments, while Surgical decreased due to inventory adjustments The impact of the dia-burs in China caused a ¥250 million decrease in 1Q; there were negative effects from September to October, but there was significant improvement from November onward DentalForeign exchange MANI Dental (excluding the impact of dia-burs in China) +216 Increase in Europe MMG* (10) Decrease due to sluggish sales in Europe, despite increased orders in North America Surgical Eyeless Needle (49) +93 +206+173 7,655 7,828 FY25 1Q FY26 1Q (250) China dia-burs 1Q sales difference Decrease due to inventory adjustment in China and lower demand in other regions Increased sales mainly in Thailand, India, and China *Note: MMG = German subsidiary MANI MEDICAL GERMANY GmbH (¥ million)
Page 11
2023年8月期 第2四半期決算説明資料 業績予想 トピックス 補足資料業績概要 11 FY2026 1Q Financial Results Americas Europe Other regionsAsiaJapan Achieved steady global sales growth Growth in Asia: Increase in sales of eyeless needles, mainly in Thailand and India Decrease in sales of the Surgical segment in other regions (due to temporary factors) (88) 7,655 7,828 +15 +19 +77 +150 Net Sales Status by Region • China (88) • Thailand +182 • India +97 • Others (41) Russia (100) Others ＋12 FY25 1Q FY26 1Q • North America +36 • Central and South America (17) (¥ million)
Page 12
2023年8月期 第2四半期決算説明資料 業績予想 トピックス 補足資料業績概要 12 FY2026 1Q Financial Results Increase in operating income YoY +¥148 million [7.0%] Foreign exchange impact +¥121 million, and improved cost ratio +¥37 million contributed to gross profit improvement SG&A expenses were almost as planned FY26 1QFY25 1Q 2,107 2,255 Net sales Analysis for Gross profit • Foreign exchange impact +121 • Cost ratio improvement +37 Cost of sales Elimination of previous performance- linked bonuses (temporary factor) SG&A expenses • Strengthening in the U.S. • Strengthening in Asia • Improvement in MMG +173 (15) +175 (185) SG&A expenses impact (10) Gross profit impact +158 Operating Income Status (¥ million)
Page 13
2023年8月期 第2四半期決算説明資料 業績予想 トピックス 補足資料業績概要 13 FY2026 1Q Financial Results Surgical Segment – Results Analysis FY24 FY25 FY26 Item 1Q 2Q 3Q 4Q 1Q 2Q 3Q 4Q 1Q YoY QoQ Net sales 1,945 1,841 2,214 2,151 2,442 2,276 2,257 2,298 2,446 100% 106% Operating income 651 592 748 647 838 804 718 718 827 99% 115% Operating income margin 34% 32% 34% 30% 34% 35% 32% 31% 34% 0pt 3pt Recorded the highest quarterly net sales. Strong sales of ophthalmic knives in Japan and Europe The growth rate from FY25 to FY26 is expected to be 109% as planned (FY25/1Q had special temporary factors) In China, the number of cataract surgeries was suppressed due to medical expense policies, resulting in high distribution inventory Expect improvement in the latter half of FY26 Overview Future Key Measures Strengthening in Europe through a capital alliance with iRIS EYE Promote alliance with MST in the U.S. Focus on marketing in Southeast Asia (Indonesia, Malaysia) 1Q YoY QoQ Japan 707 110% 105% Asia 624 95% 138% China 394 78% 142% India 28 99% 100% Europe 732 107% 112% North America 176 117% 61% Others 204 67% 90% Total 2,446 100% 106% Sales by region （¥ million）
Page 14
2023年8月期 第2四半期決算説明資料 業績予想 トピックス 補足資料業績概要 14 FY2026 1Q Financial Results FY24 FY25 FY26 Item 1Q 2Q 3Q 4Q 1Q 2Q 3Q 4Q 1Q YoY QoQ Net sales 2,520 2,454 2,855 2,392 2,844 2,711 2,776 2,850 3,006 106% 105％ Operating income 966 945 1,069 890 1,046 1,022 976 957 1,106 106% 115% Operating income margin 38% 39% 38% 37% 37% 38% 35% 34% 37% 0pt 3pt Recorded the highest quarterly net sales ‒ YoY: 106% GPO contract in China and major orders from a customer in Thailand have contributed to the YoY growth Inventory adjustments in North America and Europe have occurred Overview Future Key Measures Expand sales by taking advantage of our special needles’ product superiority (e.g. micro-surgery needles, black needles) Countermeasures against emerging market competitors ‒ Sales expansion through the acquisition of new customers ‒ Achieve fundamental reduction of manufacturing costs Customer support by launch of resin tray business Eyeless Needle Segment – Results Analysis 1Q YoY QoQ Japan 232 105% 92% Asia 1,568 116% 96% China 928 106% 97% India 183 158% 106% Europe 431 97% 117% North America 360 83% 107% Others 413 106% 155% Total 3,006 106% 105% Sales by region （¥ million）
Page 15
2023年8月期 第2四半期決算説明資料 業績予想 トピックス 補足資料業績概要 15 FY2026 1Q Financial Results FY24 FY25 FY26 Item 1Q 2Q 3Q 4Q 1Q 2Q 3Q 4Q 1Q YoY QoQ Net sales 2,648 2,498 2,631 2,360 2,368 2,167 2,435 2,538 2,375 100% 94% Operating income 605 435 482 355 222 237 267 382 322 145% 84% Operating income margin 23% 17% 18% 15% 9% 11% 11% 15% 14% 5pt (1pt) Sales recovered after the resumption of China diamond bur sales and increased sales in Europe and North America, showing a recovery trend from 2Q onward. The German subsidiary MMG is promoting reforms toward profitability. ‒ 1Q: Sales are ¥510 million, operating income is (¥70 million) ‒ Increased orders from major customers in the US led to higher sales. ‒ Started sales of own-brand products from FY26. Overview Future Key Measures Strengthen the recovery of the China Business Ongoing turnaround at German subsidiary MMG Continue expansion of JIZAI-1 and development of JIZAI-2 Dental Segment – Results Analysis 1Q YoY QoQ Japan 227 79% 44% Asia 1,398 98% 102% China 740 97% 133% India 331 110% 116% Europe 412 111% 124% North America 259 148% 142% Others 78 76% 56% Total 2,375 100% 94% Sales by region （¥ million）
Page 16
2023年8月期 第2四半期決算説明資料 業績予想 トピックス 補足資料業績概要 16 FY2026 1Q Financial Results 53,561 54,689 4,425 4,889 As of August 31, 2025 As of November 30, 2025 28,009 28,338 5,217 3,787 6,337 6,620 18,424 20,834 As of August 31, 2025 As of November 30, 2025 Balance Sheet Status Maintained strong equity capital Assets +¥1,591 million: Increase in cash and deposits due to increased free cash flow Net assets +¥1,127 million: Increase in net profit and foreign currency translation adjustments Assets Liabilities and Net Assets 57,987 57,98759,579 59,579 （¥ million） Cash & deposits Inventories Other current assets Non-current assets Net assets Liabilities
Page 17
17 This presentation contains forward-looking statements that were prepared based on available information and rational judgements by MANI, Inc. Readers are asked not to rely completely on the performance forecasts and understand that results may differ from such forecasts due to a variety of risks and uncertainties. 《Inquiry》 MANI, INC. Corporate Planning Group 8-3 Kiyohara Industrial Park, Utsunomiya, Tochigi TEL：+81 28-667-1811 Email：ir@mani.inc HP：https://www.mani.co.jp/en/ THE BEST QUALITY IN THE WORLD, TO THE WORLD
Page 18
2023年8月期 第2四半期決算説明資料 業績予想 トピックス 補足資料業績概要 18 Ⅳ Appendix
Page 19
2023年8月期 第2四半期決算説明資料 業績予想 トピックス 補足資料業績概要 19 FY2026 1Q Financial Results Quarterly Consolidated Performance （¥ million） FY24 FY25 FY26 Item 1Q 2Q 3Q 4Q 1Q 2Q 3Q 4Q 1Q Consolidated Performance Net sales 7,114 6,793 7,702 6,903 7,655 7,155 7,469 7,687 7,828 Operating income 2,223 1,974 2,300 1,893 2,107 2,064 1,963 2,057 2,255 Operating income margin 31.3% 29.1% 29.9% 27.4% 27.5% 28.9% 26.3% 26.8% 28.8% Exchange Rate USD/JPY 149.10 146.75 153.14 154.14 149.03 154.11 146.18 146.33 151.50 EUR/JPY 159.30 159.46 165.44 167.57 161.99 160.51 162.03 169.93 176.38 CNY/JPY 20.47 20.43 21.16 21.29 20.88 21.12 20.14 20.38 21.28 INR/JPY 1.79 1.77 1.84 1.84 1.77 1.79 1.70 1.69 1.71
Page 20
2023年8月期 第2四半期決算説明資料 業績予想 トピックス 補足資料業績概要 20 FY2026 1Q Financial Results Quarterly Sales by Region (Consolidated) FY24 FY25 FY26 1Q 2Q 3Q 4Q 1Q 2Q 3Q 4Q 1Q Japan 1,105 （16%） 937 (14%) 1,060 (14%) 1,102 (16%) 1,152 (15%) 1,134 (16%) 1,148 (15%) 1,436 (19%) 1,167 (15%) Asia 3,653 (51%) 3,195 (47%) 3,766 (49%) 3,278 (47%) 3,440 (45%) 3,138 (44%) 3,395 (45%) 3,451 (45%) 3,591 (46%) China 2,449 (34%) 1,888 (28%) 2,352 (31%) 1,952 (28%) 2,151 (28%) 1,724 (24%) 1,889 (25%) 1,793 (23%) 2,063 (26%) India 392 (6%) 422 (6%) 412 (5%) 457 (7%) 445 (6%) 405 (6%) 481 (6%) 486 (6%) 542 (7%) Europe 1,276 (18%) 1,443 (21%) 1,488 (19%) 1,351 (20%) 1,500 (20%) 1,332 (19%) 1,534 (21%) 1,353 (18%) 1,577 (20%) North America 655 (9%) 707 (10%) 763 (10%) 661 (10%) 760 (10%) 773 (11%) 564 (8%) 811 (11%) 796 (10%) Others 422 (6%) 508 (7%) 623 (8%) 510 (7%) 800 (10%) 776 (11%) 826 (11%) 634 (8%) 696 (9%) Total 7,114 (100%) 6,793 (100%) 7,702 (100%) 6,903 (100%) 7,655 (100%) 7,155 (100%) 7,469 (100%) 7,687 (100%) 7,828 (100%) （¥ million）
Page 21
2023年8月期 第2四半期決算説明資料 業績予想 トピックス 補足資料業績概要 21 FY2026 1Q Financial Results Quarterly Sales by Regions (Surgical Segment) FY24 FY25 FY26 1Q 2Q 3Q 4Q 1Q 2Q 3Q 4Q 1Q Japan 636 (33%) 529 (29%) 642 (29%) 653 (30%) 643 (26%) 648 (28%) 669 (30%) 673 (29%) 707 (29%) Asia 547 (28%) 499 (27%) 606 (27%) 540 (25%) 660 (27%) 642 (28%) 678 (30%) 453 (20%) 624 (26%) China 424 (22%) 351 (19%) 436 (20%) 377 (18%) 508 (21%) 439 (19%) 484 (21%) 278 (12%) 394 (16%) India 29 (2%) 24 (1%) 30 (1%) 30 (1%) 28 (1%) 27 (1%) 32 (1%) 28 (1%) 28 (1%) Europe 450 (23%) 517 (28%) 609 (27%) 595 (28%) 682 (28%) 596 (26%) 655 (29%) 652 (28%) 732 (30%) North America 83 (4%) 133 (7%) 172 (8%) 177 (8%) 151 (6%) 205 (9%) 42 (2%) 292 (13%) 176 (7%) Others 228 (12%) 161 (9%) 186 (8%) 184 (9%) 305 (12%) 182 (8%) 211 (9%) 227 (10%) 204 (8%) Total 1,945 (100%) 1,841 (100%) 2,215 (100%) 2,151 (100%) 2,442 (100%) 2,276 (100%) 2,257 (100%) 2,298 (100%) 2,446 (100%) （¥ million）
Page 22
2023年8月期 第2四半期決算説明資料 業績予想 トピックス 補足資料業績概要 22 FY2026 1Q Financial Results Quarterly Sales by Regions (Eyeless Needle Segment) FY24 FY25 FY26 1Q 2Q 3Q 4Q 1Q 2Q 3Q 4Q 1Q Japan 190 (8%) 204 (8%) 219 (8%) 222 (9%) 222 (8%) 229 (8%) 250 (9%) 251 (9%) 232 (8%) Asia 1,227 (49%) 1,221 (50%) 1,395 (49%) 1,228 (51%) 1,351 (48%) 1,317 (49%) 1,343 (48%) 1,625 (57%) 1,568 (52%) China 790 (31%) 711 (29%) 873 (31%) 738 (31%) 878 (31%) 836 (31%) 705 (25%) 958 (34%) 928 (31%) India 101 (4%) 115 (5%) 105 (4%) 135 (6%) 116 (4%) 76 (3%) 126 (5%) 172 (6%) 183 (6%) Europe 481 (19%) 383 (16%) 424 (15%) 404 (17%) 445 (16%) 398 (15%) 428 (15%) 370 (13%) 431 (14%) North America 441 (18%) 450 (18%) 432 (15%) 307 (13%) 433 (15%) 407 (15%) 358 (13%) 337 (12%) 360 (12%) Others 180 (7%) 194 (8%) 386 (14%) 229 (10%) 391 (14%) 359 (13%) 395 (14%) 266 (9%) 413 (14%) Total 2,520 (100%) 2,454 (100%) 2,856 (100%) 2,392 (100%) 2,844 (100%) 2,711 (100%) 2,776 (100%) 2,850 (100%) 3,006 (100%) （¥ million）
Page 23
2023年8月期 第2四半期決算説明資料 業績予想 トピックス 補足資料業績概要 23 FY2026 1Q Financial Results Quarterly Sales by Regions (Dental Segment) FY24 FY25 FY26 1Q 2Q 3Q 4Q 1Q 2Q 3Q 4Q 1Q Japan 279 (11%) 204 (8%) 200 (8%) 226 (10%) 287 (12%) 255 (12%) 228 (9%) 511 (20%) 227 (10%) Asia 1,878 (71%) 1,474 (59%) 1,766 (67%) 1,509 (64%) 1,428 (60%) 1,179 (54%) 1,373 (56%) 1,372 (54%) 1,398 (59%) China 1,234 (47%) 825 (33%) 1,042 (40%) 837 (35%) 763 (32%) 447 (21%) 699 (29%) 556 (22%) 740 (31%) India 261 (10%) 282 (11%) 278 (11%) 292 (12%) 300 (13%) 300 (14%) 322 (13%) 285 (11%) 331 (14%) Europe 345 (13%) 542 (22%) 455 (17%) 350 (15%) 373 (16%) 337 (16%) 450 (19%) 331 (13%) 412 (17%) North America 130 (5%) 123 (5%) 160 (6%) 176 (7%) 175 (7%) 160 (7%) 163 (7%) 181 (7%) 259 (11%) Others 14 (1%) 153 (6%) 51 (2%) 97 (4%) 103 (4%) 234 (11%) 219 (9%) 140 (6%) 78 (3%) Total 2,648 (100%) 2,498 (100%) 2,631 (100%) 2,360 (100%) 2,368 (100%) 2,167 (100%) 2,435 (100%) 2,538 (100%) 2,375 (100%) （¥ million）
Page 24
2023年8月期 第2四半期決算説明資料 業績予想 トピックス 補足資料業績概要 24 FY2026 1Q Financial Results Cumulative Consolidated Performance FY24 FY25 FY26 Item 1Q 2Q 3Q 4Q 1Q 2Q 3Q 4Q 1Q Consolidated Performance Net sales 7,114 13,908 21,610 28,513 7,655 14,810 22,280 29,968 7,828 Operating income 2,223 4,197 6,498 8,392 2,107 4,172 6,135 8,193 2,255 Operating income margin 31.3% 30.2% 30.1% 29.4% 27.5% 28.2% 27.5% 27.3% 28.8% Exchange Rate USD/JPY 149.10 147.92 149.66 150.78 149.03 151.57 149.77 148.91 151.50 EUR/JPY 159.30 159.38 161.40 162.94 161.99 161.25 161.51 163.62 176.38 CNY/JPY 20.47 20.45 20.68 20.84 20.88 21.00 20.71 20.63 21.28 INR/JPY 1.79 1.78 1.80 1.81 1.77 1.78 1.76 1.74 1.71 （¥ million）
Page 25
2023年8月期 第2四半期決算説明資料 業績予想 トピックス 補足資料業績概要 25 FY2026 1Q Financial Results Surgical instruments, such as ophthalmic knives and skin staplers Competitive advantages: Superior sharpness and microfabrication technology that adapts to surgical miniaturization and precision Contribution to shortening operation time, reducing the burden on the human body, and preventing postoperative complications Surgical suture needles, needles for surgical sutures (OEM production) Competitive advantages The accumulation of our microfabrication technology and our original material development High penetrability and resistance to breakage Wide variety of needles to meet customer needs (Diverse lineup of 10,000 types of needles) Dental instruments, dental restoration materials Competitive advantages： Dental endodontic instruments’ excellent durability and centering ability towards root canal Dental restorative materials that do not contain environmental hormones and are easy for dentists to use Dia-burs and reamers/files have high market shares (Top market share in Asia) Product Segments Surgical Eyeless Needle Dental Ophthalmic Knives (used for cataract surgery) Skin stapler Eyeless Needle Eyed Needle Dental Endodontic Instruments (Reamers/Files) Dental Restoration Material Dental Rotary and Cutting Instruments (Dia-burs)
Page 26
2023年8月期 第2四半期決算説明資料 業績予想 トピックス 補足資料業績概要 26 FY2026 1Q Financial Results Europe ¥5.72 billion (19.1%) North America ¥2.91 billion(9.7%) Others ¥3.03 billion (10.1%) Asia ¥13.43 billion (44.8%) Japan ¥4.87 billion (16.3%) Consolidated sales ¥30 billion ※As of August 31, 2025 Company Overview THE BEST QUALITY IN THE WORLD, TO THE WORLD Sales region Over120 countries/regions Ophthalmic knives global share approx.30％ Overseas sales ratio 83.7% Company Name MANI, INC. Representative CEO Masaya Watanabe Stock code 7730 Employees 432 (consolidated: 4,140) （as of August 31, 2025） Established 1956 Capital ¥1,087 million（as of August 31, 2025） Head Office 8-3 Kiyohara Industrial Park, Utsunomiya, Tochigi
Page 27
2023年8月期 第2四半期決算説明資料 業績予想 トピックス 補足資料業績概要 27 FY2026 1Q Financial Results R&D base, production base and sales base Sales base Production base Production base Production base and sales base Sales base Headquarters Sales base Germany (Frankfurt) MANI MEDICAL GERMANY GmbH (formally GDF) India（Delhi） MANI MEDICAL INDIA PRIVATE LIMITED Myanmar (Yangon) MANI YANGON LTD. Malaysia (Kuala Lumpur) MANI MEDICAL DEVICE MALAYSIA SDN. BHD. Laos（Vientiane） MANI VIENTIANE SOLE CO., LTD. Vietnam (Hanoi) MANI MEDICAL HANOI CO., LTD MANI HANOI CO., LTD. China (Beijing) MANI Medical Beijing Co., Ltd. America (California) MANI MEDICAL AMERICA, INC. Japan (Tochigi) MANI, INC. Global Network Sales base China (Foshan) MANI China (Foshan) Co., Ltd. Production base
Page 28
2023年8月期 第2四半期決算説明資料 業績予想 トピックス 補足資料業績概要 28 FY2026 1Q Financial Results 0 50 100 150 200 250 300 350 1960 1970 1980 1990 2000 2010 2020 Since our foundation, MANI has consistently worked on the development, production, and sales of consumer healthcare products and expanding its business 1996: Established production base in Vietnam 2010 onward: Established overseas sales bases (Vietnam ⇒ China ⇒ India ⇒ Malaysia ⇒ USA) 2015: Acquired German company (MMG) in the dental field, also seeking business synergies History （¥ 100 million） 2025 ¥300 million 1961 Manufactured the world’s first rust- proof and unbreakable stainless-steel needles World Share 20％ 1976 Launched stainless- steel dental broaches 1979 Launched reamers/files World Share 30％ 1988 Launched dia-burs World Share 15％ 1993 Launched skin staplers 1998 Launched our core product ophthalmic knives World Share 30％ 2015 Began supplying composite resin with the acquisition of GDF (currently MMG) 2020 Started sales of endodontic rotary instruments using highly flexible nickel titanium 2023 Launched vitreous forceps for treating internal ocular diseases
Page 29
2023年8月期 第2四半期決算説明資料 業績予想 トピックス 補足資料業績概要 29 FY2026 1Q Financial Results 47 56 67 76 82 88 93 94 95 97 93 114 138 166 172 201 183 152 172 204 245 285 300 328 32% 35% 37% 39% 41% 39% 37% 38% 37% 36% 32% 34% 30%26% 25% 25% 32% 29% 31% 30% 30% 29% 27% 28% 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 Lehman Shock COVID-19 • Achieve both sales growth and high profit margins • Business model that has resilience in the recession period (high income margin even in the event of the Lehman shock and COVID-19 shock) Net sales Operating income margin (¥ million) Achieving Long-Term Growth
Page 30
30